Tumor Necrosis Factor Inhibitor Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars); Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others); Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies)

Report Code: TIPRE00021605 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Get Free Sample PDF
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

TNF inhibitors are drugs used against inflammation. These are used to treat diseases such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile arthritis, plaque psoriasis, ulcerative colitis (UC), ankylosing spondylitis, and Crohn's disease. These are also known as TNF blockers, biologic therapies, or anti-TNF drugs.

MARKET DYNAMICS

The tumor necrosis factor inhibitor drugs market is driving due to the increasing incidence of autoimmune diseases, and product launches by market players. Moreover, growing awareness for tumor necrosis factor (TNF) in developed as well as developing countries is likely to create growth opportunities in the market.

MARKET SCOPE

The "Tumor Necrosis Factor Inhibitor Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of tumor necrosis factor inhibitor drugs market with detailed market segmentation by product type, application and distribution channel. The tumor necrosis factor inhibitor drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in tumor necrosis factor inhibitor drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The tumor necrosis factor inhibitor drugs market is segmented on the basis of product type, application and distribution channel. Based on product type the market is segmented humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. Application segment is segmented into rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others. Based on distribution channel the market is segmented into hospital pharmacies, specialty pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the tumor necrosis factor inhibitor drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The tumor necrosis factor inhibitor drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting tumor necrosis factor inhibitor drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Tumor necrosis factor inhibitor drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the tumor necrosis factor inhibitor drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from tumor necrosis factor inhibitor drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for tumor necrosis factor inhibitor drugs in the global market. Below mentioned is the list of few companies engaged in the tumor necrosis factor inhibitor drugs market.

The report also includes the profiles of key players in tumor necrosis factor inhibitor drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

    1. AbbVie Inc.
    2. Amgen Inc.
    3. Johnson and Johnson Services, Inc.
    4. UCB S.A.
    5. Novartis International AG
    6. Pfizer, Inc.
    7. Merck and co., Inc.
    8. Boehringer Ingelheim Pharmaceuticals, Inc.
    9. GlaxoSmithKline plc.
    10. Bristol-Myers Squibb Company

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Tumor Necrosis Factor Inhibitor Drugs Market - By Product Type
1.3.2 Tumor Necrosis Factor Inhibitor Drugs Market - By Application
1.3.3 Tumor Necrosis Factor Inhibitor Drugs Market - By Distribution Channel
1.3.4 Tumor Necrosis Factor Inhibitor Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. TUMOR NECROSIS FACTOR INHIBITOR DRUGS - GLOBAL MARKET OVERVIEW
6.2. TUMOR NECROSIS FACTOR INHIBITOR DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. HUMIRA
7.3.1. Overview
7.3.2. Humira Market Forecast and Analysis
7.4. ENBREL
7.4.1. Overview
7.4.2. Enbrel Market Forecast and Analysis
7.5. REMICADE
7.5.1. Overview
7.5.2. Remicade Market Forecast and Analysis
7.6. SIMPONI/SIMPONI ARIA
7.6.1. Overview
7.6.2. Simponi/Simponi Aria Market Forecast and Analysis
7.7. CIMZIA
7.7.1. Overview
7.7.2. Cimzia Market Forecast and Analysis
7.8. BIOSIMILARS
7.8.1. Overview
7.8.2. Biosimilars Market Forecast and Analysis
8. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. RHEUMATOID ARTHRITIS
8.3.1. Overview
8.3.2. Rheumatoid Arthritis Market Forecast and Analysis
8.4. PSORIASIS
8.4.1. Overview
8.4.2. Psoriasis Market Forecast and Analysis
8.5. PSORIATIC ARTHRITIS
8.5.1. Overview
8.5.2. Psoriatic Arthritis Market Forecast and Analysis
8.6. CROHN'S DISEASE
8.6.1. Overview
8.6.2. Crohn's Disease Market Forecast and Analysis
8.7. ULCERATIVE COLITIS
8.7.1. Overview
8.7.2. Ulcerative Colitis Market Forecast and Analysis
8.8. ANKYLOSING SPONDYLITIS
8.8.1. Overview
8.8.2. Ankylosing Spondylitis Market Forecast and Analysis
8.9. JUVENILE IDIOPATHIC ARTHRITIS
8.9.1. Overview
8.9.2. Juvenile Idiopathic Arthritis Market Forecast and Analysis
8.10. HIDRADENITIS SUPPURATIVA
8.10.1. Overview
8.10.2. Hidradenitis Suppurativa Market Forecast and Analysis
8.11. OTHERS
8.11.1. Overview
8.11.2. Others Market Forecast and Analysis
9. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. SPECIALTY PHARMACIES
9.4.1. Overview
9.4.2. Specialty Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Tumor Necrosis Factor Inhibitor Drugs Market Overview
10.1.2 North America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis
10.1.3 North America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Product Type
10.1.4 North America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Application
10.1.5 North America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Tumor Necrosis Factor Inhibitor Drugs Market
10.1.6.1.1 United States Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.1.6.1.2 United States Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.1.6.1.3 United States Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.1.6.2 Canada Tumor Necrosis Factor Inhibitor Drugs Market
10.1.6.2.1 Canada Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.1.6.2.2 Canada Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.1.6.2.3 Canada Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.1.6.3 Mexico Tumor Necrosis Factor Inhibitor Drugs Market
10.1.6.3.1 Mexico Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.1.6.3.2 Mexico Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.1.6.3.3 Mexico Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
10.2.2 Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis
10.2.3 Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Product Type
10.2.4 Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Application
10.2.5 Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.1.1 Germany Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.1.2 Germany Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.1.3 Germany Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2.6.2 France Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.2.1 France Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.2.2 France Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.2.3 France Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2.6.3 Italy Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.3.1 Italy Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.3.2 Italy Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.3.3 Italy Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2.6.4 Spain Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.4.1 Spain Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.4.2 Spain Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.4.3 Spain Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.5.1 United Kingdom Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.5.2 United Kingdom Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.5.3 United Kingdom Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market
10.2.6.6.1 Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.2.6.6.2 Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.2.6.6.3 Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Overview
10.3.2 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Product Type
10.3.4 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.1.1 Australia Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.1.2 Australia Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.1.3 Australia Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3.6.2 China Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.2.1 China Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.2.2 China Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.2.3 China Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3.6.3 India Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.3.1 India Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.3.2 India Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.3.3 India Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3.6.4 Japan Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.4.1 Japan Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.4.2 Japan Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.4.3 Japan Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3.6.5 South Korea Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.5.1 South Korea Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.5.2 South Korea Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.5.3 South Korea Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.3.6.6.2 Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.3.6.6.3 Rest of Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Overview
10.4.2 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Product Type
10.4.4 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Tumor Necrosis Factor Inhibitor Drugs Market
10.4.6.1.1 South Africa Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.4.6.1.2 South Africa Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.4.6.1.3 South Africa Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market
10.4.6.2.1 Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.4.6.2.2 Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.4.6.2.3 Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.4.6.3 U.A.E Tumor Necrosis Factor Inhibitor Drugs Market
10.4.6.3.1 U.A.E Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.4.6.3.2 U.A.E Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.4.6.3.3 U.A.E Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.4.6.4.2 Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.4.6.4.3 Rest of Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Overview
10.5.2 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis
10.5.3 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Product Type
10.5.4 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Application
10.5.5 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Tumor Necrosis Factor Inhibitor Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Tumor Necrosis Factor Inhibitor Drugs Market
10.5.6.1.1 Brazil Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.5.6.1.2 Brazil Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.5.6.1.3 Brazil Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.5.6.2 Argentina Tumor Necrosis Factor Inhibitor Drugs Market
10.5.6.2.1 Argentina Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.5.6.2.2 Argentina Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.5.6.2.3 Argentina Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Tumor Necrosis Factor Inhibitor Drugs Market
10.5.6.3.1 Rest of South and Central America Tumor Necrosis Factor Inhibitor Drugs Market by Product Type
10.5.6.3.2 Rest of South and Central America Tumor Necrosis Factor Inhibitor Drugs Market by Application
10.5.6.3.3 Rest of South and Central America Tumor Necrosis Factor Inhibitor Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. TUMOR NECROSIS FACTOR INHIBITOR DRUGS MARKET, KEY COMPANY PROFILES
13.1. ABBVIE INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. AMGEN INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. JOHNSON AND JOHNSON SERVICES, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. UCB S.A.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. NOVARTIS INTERNATIONAL AG
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. PFIZER, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MERCK AND CO., INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GLAXOSMITHKLINE PLC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BRISTOL-MYERS SQUIBB COMPANY
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Amgen Inc.
3. Johnson and Johnson Services, Inc.
4. UCB S.A.
5. Novartis International AG
6. Pfizer, Inc.
7. Merck and co., Inc.
8. Boehringer Ingelheim Pharmaceuticals, Inc.
9. GlaxoSmithKline plc.
10. Bristol-Myers Squibb Company
TIPRE00021605
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking